Olmesta
Generic Name
Olmesartan Medoxomil
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| olmesta 40 mg tablet | ৳ 18.00 | ৳ 180.00 |
Description
Overview of the medicine
Olmesta 40 mg Tablet contains Olmesartan Medoxomil, an angiotensin II receptor blocker (ARB) used to treat high blood pressure (hypertension). It helps to lower blood pressure, which can prevent strokes, heart attacks, and kidney problems.
Uses & Indications
Dosage
Adults
The usual recommended starting dose is 20 mg once daily. The dose can be increased to 40 mg once daily if blood pressure is not adequately controlled. Maximum recommended dose is 40 mg daily.
Elderly
No initial dosage adjustment is typically required, but monitoring of renal function is recommended.
Renal_impairment
For patients with severe renal impairment (creatinine clearance <20 ml/min), a starting dose of 10 mg once daily is recommended, with careful monitoring.
How to Take
Olmesta tablets should be taken orally, once daily, with or without food. It is recommended to take it at approximately the same time each day.
Mechanism of Action
Olmesartan Medoxomil is a prodrug that is rapidly converted to its active metabolite, olmesartan, during absorption from the gastrointestinal tract. Olmesartan selectively blocks the binding of angiotensin II to the AT1 receptor in various tissues, including vascular smooth muscle and the adrenal gland. This blockade inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation, decreased blood pressure, and reduced fluid retention.
Pharmacokinetics
Onset
Blood pressure reduction is apparent within 1 week, with maximal effect seen after 2 weeks of therapy.
Excretion
Approximately 30-50% of the absorbed dose is excreted renally (urine) and the remainder is eliminated via the hepatobiliary route (faeces).
Half life
Elimination half-life of olmesartan is approximately 13-15 hours.
Absorption
Rapidly and completely absorbed from the GI tract, converting to active olmesartan. Absolute bioavailability is approximately 26%. Peak plasma concentrations are reached within 1-2 hours.
Metabolism
Olmesartan Medoxomil is completely hydrolyzed to active olmesartan by esterases in the gut wall and blood during absorption. Olmesartan itself is not significantly metabolized by the cytochrome P450 system.
Side Effects
Contraindications
- Hypersensitivity to the active substance or to any of the excipients.
- Second and third trimesters of pregnancy.
- Biliary obstruction.
- Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (GFR <60 ml/min/1.73 m²).
Drug Interactions
Lithium
Concurrent use may increase serum lithium concentrations and lead to lithium toxicity.
Diuretics and other antihypertensive agents
May increase the hypotensive effect.
Non-steroidal anti-inflammatory drugs (NSAIDs)
May reduce the antihypertensive effect and increase the risk of renal impairment, especially in elderly or dehydrated patients.
Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium
May lead to increased serum potassium levels (hyperkalemia).
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.
Overdose
The most likely manifestation of overdose is hypotension (low blood pressure) and possibly tachycardia; bradycardia could occur from parasympathetic stimulation. Treatment is symptomatic and supportive. If ingestion is recent, gastric lavage may be considered. Olmesartan is not dialyzable.
Pregnancy & Lactation
Olmesartan is contraindicated in the second and third trimesters of pregnancy due to the risk of fetal injury and death. Use in the first trimester is not recommended. It is not known whether olmesartan is excreted in human milk, so caution should be exercised when administered to a nursing woman.
Side Effects
Contraindications
- Hypersensitivity to the active substance or to any of the excipients.
- Second and third trimesters of pregnancy.
- Biliary obstruction.
- Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (GFR <60 ml/min/1.73 m²).
Drug Interactions
Lithium
Concurrent use may increase serum lithium concentrations and lead to lithium toxicity.
Diuretics and other antihypertensive agents
May increase the hypotensive effect.
Non-steroidal anti-inflammatory drugs (NSAIDs)
May reduce the antihypertensive effect and increase the risk of renal impairment, especially in elderly or dehydrated patients.
Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium
May lead to increased serum potassium levels (hyperkalemia).
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.
Overdose
The most likely manifestation of overdose is hypotension (low blood pressure) and possibly tachycardia; bradycardia could occur from parasympathetic stimulation. Treatment is symptomatic and supportive. If ingestion is recent, gastric lavage may be considered. Olmesartan is not dialyzable.
Pregnancy & Lactation
Olmesartan is contraindicated in the second and third trimesters of pregnancy due to the risk of fetal injury and death. Use in the first trimester is not recommended. It is not known whether olmesartan is excreted in human milk, so caution should be exercised when administered to a nursing woman.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from the date of manufacture.
Availability
Available in pharmacies and hospitals
Approval Status
Approved by major regulatory bodies (e.g., FDA, DGDA)
Patent Status
Off-patent
Clinical Trials
Key trials for Olmesartan include the VALUE trial (assessed cardiovascular morbidity and mortality) and the ROADMAP study (examined renal outcomes in type 2 diabetes).
Lab Monitoring
- Serum electrolytes (especially potassium) before and periodically during treatment.
- Renal function (serum creatinine, BUN) before and periodically during treatment.
Doctor Notes
- Monitor blood pressure regularly, especially during initiation and dose titration.
- Assess renal function and serum potassium levels before starting treatment and periodically thereafter, particularly in high-risk patients.
- Advise patients on lifestyle modifications (diet, exercise, sodium restriction) to enhance blood pressure control.
- Counsel female patients of childbearing potential on the risk of fetal toxicity if pregnant.
Patient Guidelines
- Take the medicine exactly as prescribed by your doctor.
- Do not stop taking the medicine suddenly without consulting your doctor.
- Monitor your blood pressure regularly as advised by your healthcare provider.
- Inform your doctor if you experience dizziness, fainting, or swelling of the face or throat.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Olmesartan may cause dizziness or lightheadedness, especially at the start of treatment or when the dose is increased. Patients should be cautioned about operating machinery or driving until they know how the medication affects them.
Lifestyle Advice
- Adopt a healthy lifestyle including a balanced diet rich in fruits and vegetables, and low in saturated fats and sodium.
- Engage in regular physical activity as recommended by your doctor.
- Limit alcohol intake and avoid smoking.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Olmesta Brand
Other medicines available under the same brand name
